As of close of business last night, Cardlytics Inc’s stock clocked out at $13.14, down -3.17% from its previous closing price of $13.57. On the day, 1070753 shares were traded. CDLX stock price reached its highest trading level at $13.77 during the session, while it also had its lowest trading level at $13.03.
Ratios:
To gain a deeper understanding of CDLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 1.97 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Craig Hallum on March 15, 2024, Upgraded its rating to Buy and sets its target price to $18 from $10 previously.
On November 29, 2023, Lake Street started tracking the stock assigning a Buy rating and target price of $13.
Wells Fargo Downgraded its Equal Weight to Underweight on September 08, 2022, whereas the target price for the stock was revised from $14 to $13.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Temsamani Karim Saad sold 32,564 shares for $13.69 per share. The transaction valued at 445,801 led to the insider holds 344,734 shares of the business.
Lynton Nicholas Hollmeyer sold 12,460 shares of CDLX for $170,620 on Apr 02 ’24. The Chief Legal & Privacy Officer now owns 71,355 shares after completing the transaction at $13.69 per share. On Apr 01 ’24, another insider, Temsamani Karim Saad, who serves as the Chief Executive Officer of the company, sold 154 shares for $14.41 each. As a result, the insider received 2,219 and left with 344,580 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.87 while its Price-to-Book (P/B) ratio in mrq is 3.87.
Stock Price History:
Over the past 52 weeks, CDLX has reached a high of $20.52, while it has fallen to a 52-week low of $4.94.
Shares Statistics:
A total of 44.11M shares are outstanding, with a floating share count of 41.10M. Insiders hold about 6.83% of the company’s shares, while institutions hold 68.14% stake in the company.
Earnings Estimates
As of right now, Celldex Therapeutics, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $140.53, with high estimates of $29.42 and low estimates of $0.82.
Analysts are recommending an EPS of between $Technology and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Defensive.
